Lilly's Zepbound-amylin combination drives significant weight loss in phase 2
High discontinuation rates in the mid-stage study raise tolerability questions for the investigational combination.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 10:15 ETSource: STAT
The wire
- 01Eli Lilly reported that an investigational combination of Zepbound (tirzepatide) with an amylin drug produced significant weight loss in a mid-stage trial.
- 02Amylin analogs are the most watched add-on class to incretin therapy, and combination tolerability will shape how prescribers sequence obesity treatment.
- 03STAT reports high discontinuation rates in the study; durability and dosing strategy remain unresolved pending later-stage data.
From the source
Read at statnews.comSTAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
